echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Children's drug "unicorn" lurking new three board 2017 net profit has been nearly 100 million yuan

    Children's drug "unicorn" lurking new three board 2017 net profit has been nearly 100 million yuan

    • Last Update: 2021-02-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    At the beginning of the Year of the Dog, the disclosure of the new three-board annual report began to reach a climax. The annual reports of a group of star companies are particularly noteworthy.
    This is not, the new three-board proposed IPO of children's pharmaceutical company leader Sanli Pharmaceuticals recently released its 2017 annual report, the company in 2017 revenue of 638 million yuan, up 24.01% YoY, the home net profit of 87.6282 million yuan, up 17.03% YoY. At the same time, the Company intends to base its existing share capital of 367 million shares on an unequibuted profit of 1.92 yuan per 10 shares to all shareholders, for a total of 70.3838 million yuan.
    note that since the listing of the new three boards in August 2015, as of the recent announcement of the 2017 dividend plan, Sanli Pharmaceuticals has issued a total of 179 million yuan. And along with large dividends, Sanli Pharmaceutical's performance in recent years is also showing a high-speed growth trend, 2013-2017 net profit on the basis of 10 million levels to achieve a compound growth rate of 45.84 percent.
    Rhino Star noted that behind sanli pharmaceutical bright business performance, is China's throat disease in the traditional medicine market demand is expanding, at the same time, as a Chinese medicine production enterprises located in Guizhou region, Sanli pharmaceutical by virtue of location, product groups, dosage form composition and other unique advantages, in recent years, the market share of products is also rising.fist products dominate the market segment
    Sanli Pharmaceuticals mainly throat diseases, cardiovascular diseases and other diseases of chinese medicine research and development, production and sales. The company's fist products for the throat sword spray, in 2017 the throat sword spray accounted for 81.20% of the company's revenue, gross profit accounted for 83.73 percent. In addition, the company's other products such as the powerful Tian Ma Duzhong capsules, musk positive gas capsules also show greater development potential.
    data show that the throat sword spray from the classic Miao medical examination, its group of the main drugs for the eight claw golden dragon, mountain bean root, molybdil, as well as plant mint purified out of the white crystal - mint brain, of which eight claw golden dragon is the southeastern region of Guizhou, the authentic medicinal herbs, you are the chinese medicine, mainly used to treat sore throat.
    Because of the natural and stable quality raw materials of the open throat sword spray, it is a rare child-specific drug used in oral throat disease in China, which has been welcomed by the majority of children's patients and hospitals in recent years. In this regard, Sanli Pharmaceuticals said that the company's throat sword spray opponent foot and mouth disease, pharyngitis, tonsillitis, herpes pharyngitis, mouth ulcers and other children's most common respiratory infections have obvious advantages, the overall treatment efficiency of up to 97%.
    It is well known that children are a high incidence of throat diseases, and at this stage of clinical commonly used tablets, capsules, granules and other oral drugs in the use of the process need to go through the gastrointestinal, liver absorption after distribution throughout the body, can not directly act on the lesions, starting Slow efficacy, poor targeting, low biousability, and may cause damage to the liver, while Sanli Pharmaceutical's throat sword spray is a spray type of drug, safe and effective, and easy to use, more suitable for children with difficulty in taking the drug.
    With relatively mild raw materials and significant therapeutic effects, so far, in the spray hospital market, Sanli Pharmaceutical's throat sword spray has been the highest for four consecutive years, and in the throat disease in the pharmaceutical spray market has also overtaken Guilin watermelon cream spray and occupied the top position. In the throat disease Chinese medicine market and throat disease Chinese medicine hospital terminal market, the throat sword spray ranked 4th and 3rd, respectively.
    Sanli Pharmaceuticals said, as the country's exclusive varieties of throat sword spray, in accordance with the current norms of China's hospital drug procurement adjustment, the procurement of exclusive drugs through the manufacturer and procurement agencies to negotiate the decision, so the company has a higher pricing autonomy for the product."two-child" policy brings new opportunities
    With the full liberalization of the "two-child" policy, China will usher in the fourth baby boom, the number of children will continue to grow in the next decade. By 2024, the proportion of children is expected to reach 18.3 per cent, or about 265 million.
    the promotion of multiple positive policies, the market demand for children's medicine will undoubtedly maintain a high-speed growth trend for some time to come. At the same time, children's diagnosis and treatment is the pain point of the domestic medical industry, the urgent need for systematic service supply.
    data show that between 2002 and 2014, children's outpatient clinics grew rapidly, with a compound annual growth rate of about 6%, but China's pediatrician gap is huge, according to statistics, China's pediatrician gap of at least 200,000, children's diagnosis and treatment industry supply contradictions.
    as the country's supply side of the short board, into 2018, children's drug use frequently ushered in the policy east wind. It is reported that the Regulations on the Protection of Children's Drug Use have been submitted to the Legal Affairs Office of the State Council and are expected to be issued in the near future, and according to industry sources, the National People's Congress Education, Science, Science, Education and Health Commission has recommended that relevant departments of the State Council speed up the legislative process, actively study and absorb the opinions and suggestions put forward by deputies to the National People's Congress, and constantly improve the system of drug protection for children.
    , rhino star also from the National People's Congress Education, Science, Science and Health Commission website further learned that the revision of drug management law has been included in the Npcs Standing Committee legislative planning. At present, the State Administration of Food and Drug Administration is studying and drafting a revised draft, which is intended to provide at the legal level for priority review and approval, conditional approval, market exclusive period and other incentive policies to explicitly include children's drug use in the scope of encouragement.
    the field of throat disease, which is the main focus of Sanli Pharmaceuticals, will undoubtedly also benefit. According to statistics from the Southern Economic Research Institute, from 2011 to 2016, the overall market sales of Chinese medicines for throat diseases in China increased from 7.207 billion yuan to 13.653 billion yuan, with a compound growth rate of 13.63 percent.
    with the rapid growth of the overall industry market demand, as well as the national attention to the field of children's medicine, the development of Sanli Pharmaceutical Company has added a lot of imagination space.
    listing in 2015, Sanli Pharmaceuticals has completed two rounds of financing, raising a total of 264 million yuan. Among them, the first fixed increase is mainly aimed at Guangfa Securities and Guohai Securities two market-making companies. The second fixed increase, it obtained The Guizhou Province Wenkang Pharmaceutical and Health Industry Investment Fund, TongTron Weiye, The Times Bole Department, the public and growth investment, including 13 institutions to participate in the subscription. Based on the company's second fixed price increase of 12.5 yuan per share, Sanli Pharmaceutical's valuation is 4.588 billion yuan. (Rhino Star)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.